ATC Group: A07EC02 Mesalazine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A07EC02 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents
3 A07E Intestinal antiinflammatory agents
4 A07EC Aminosalicylic acid and similar agents
5 A07EC02 Mesalazine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1.5 g
RECTAL - Rectal 1.5 g

Active ingredients in A07EC02

Active Ingredient Description

Mesalazine is an aminosalicylate. The mechanism of action of mesalazine is not fully understood, but appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

Related product monographs

Title Information Source Document Type  
ASACOLON Gastro-resistant tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
ASACOLON Suppository Health Products Regulatory Authority (IE) MPI, EU: SmPC
MECOLZINE Gastro-resistant tablet Web Search MPI, EU: SmPC
MECOLZINE Suppository Web Search MPI, EU: SmPC
MESASAL Enteric-coated tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
MEZAVANT XL Gastro-resistant, prolonged release tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PENTASA Prolonged release granules Health Products Regulatory Authority (IE) MPI, EU: SmPC
PENTASA Suppository Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ROWASA Rectal suspension FDA, National Drug Code (US) MPI, US: SPL/Old
SALOFALK Gastro-resistant tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Albania (AL)

Croatia (HR)

Finland (FI)

France (FR)

Hong Kong (HK)

Israel (IL)

Japan (JP)

New Zealand (NZ)

Nigeria (NG)

Singapore (SG)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.